Cargando…

Prevalence of CYP2D62, CYP2D64, CYP2D610, and CYP3A53 in Thai breast cancer patients undergoing tamoxifen treatment

BACKGROUND: Tamoxifen (TAM) is used in breast cancer treatment, but interindividual variabilities in TAM-metabolizing enzymes exist and have been linked to single nucleotide polymorphisms in the respective encoding genes. The different alleles and genotypes of these genes have been presented for Cau...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charoenchokthavee, Wanaporn, Panomvana, Duangchit, Sriuranpong, Virote, Areepium, Nutthada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982506/ https://www.ncbi.nlm.nih.gov/pubmed/27540311 http://dx.doi.org/10.2147/BCTT.S105563

Ejemplares similares

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
por: Areepium, N, et al.
Publicado: (2013)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

The ethics of CYP2D6 testing for patients considering tamoxifen
por: Hartman, Anne-Renee, et al.
Publicado: (2007)

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity
por: Dalton, Rachel, et al.
Publicado: (2019)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
por: Sirachainan, Ekaphop, et al.
Publicado: (2012)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

Comparison of Paeoniflorin and Albiflorin on Human CYP3A4 and CYP2D6
por: Gao, Li-Na, et al.
Publicado: (2015)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells
por: Li, Hongfang, et al.
Publicado: (2020)

Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line
por: Lee, Hye Ja, et al.
Publicado: (2011)

Association of CYP2C19, CYP2D6 and CYP3A4 Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients
por: Macêdo, Marielle M., et al.
Publicado: (2023)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

Modulation of CYP2D6 and CYP3A4 metabolic activities by Ferula asafetida resin
por: Al-Jenoobi, Fahad I., et al.
Publicado: (2014)

Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity
por: Rodríguez-Morató, Jose, et al.
Publicado: (2019)

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
por: Chamnanphon, Montri, et al.
Publicado: (2013)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva
por: Jin, Ye, et al.
Publicado: (2022)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6(*)15 and (*)35 Genotyping
por: Riffel, Amanda K., et al.
Publicado: (2016)

Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses
por: Scantamburlo, Giada, et al.
Publicado: (2023)

Characterization of complex structural variation in the CYP2D6-CYP2D7-CYP2D8 gene loci using single-molecule long-read sequencing
por: Turner, Amy J., et al.
Publicado: (2023)

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19
por: Koopmans, Anne B., et al.
Publicado: (2021)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples
por: Collins, Joseph M., et al.
Publicado: (2023)

CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response
por: Wegman, Pia P, et al.
Publicado: (2005)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
por: Brooks, Jennifer D., et al.
Publicado: (2018)

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2020)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
por: Bezerra, Lucas Soares, et al.
Publicado: (2018)

Simple and Robust Detection of CYP2D6 Gene Deletions and Duplications Using CYP2D8P as Reference
por: Larsen, Jens Borggaard, et al.
Publicado: (2022)

Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance
por: Swart, Marelize, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mhcl2o9kpl32oshn1u8en3oulo